Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curetis AG Strengthens Commercial Team and Expands Distribution Network

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Appointment of Helmut Hilbert as Head of Business Development.

Curetis AG has announced the appointment of Helmut Hilbert as Head of Business Development and the expansion of its distribution network into Belgium and Luxembourg by closing a distribution agreement with ELITech BNL (former Lucron Bioproducts), an ELITech Group company.

In order to strengthen its global commercial operations, Curetis has hired Dr. Helmut Hilbert, formerly Associate Director Corporate Business Development at Qiagen, as Head of Business Development.

Helmut Hilbert has more than ten years of business and corporate development experience and built a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.

At Qiagen, he was responsible for scouting novel technologies as well as evaluating potential acquisition targets and investment opportunities, including contract negotiation, due diligences and post-merger integration.

Moreover, Curetis has selected ELITech BNL as its Belgian and Luxembourgian distribution partner. ELITech BNL (former Lucron Bioproducts) has a long-standing track record as a distributor of quality diagnostic products and research supplies in the Benelux.

Among others, the company supported the market entry of Cepheid into these countries.

Acquired by the global in vitro diagnostics distributor ELITech Group in 2010, ELITech BNL is part of an extensive commercial network covering France, Italy, the UK and the rest of the world.

“Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution,” said Frank Loots, General Manager of ELITech BNL.

Loots continued, “We are planning a commercial roll-out and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories.”

“With the appointment of Helmut Hilbert as Head of Business Development and the distribution agreement with ELITech, we continue our accelerated commercial development progress,” said Oliver Schacht, CEO of Curetis.

Schacht continued, “The growing awareness for the Unyvero™ System allows us to attract experienced employees and renowned corporate partners and to expand our operations. We are in the process of growing our business in the Middle East with additional placements in Dubai, Saudi Arabia and Qatar over the next couple of months. In addition, our customer order book continues to expand significantly - we currently have a waiting list of more than fifty top-tier institutions worldwide.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples.
Wednesday, December 12, 2012
Curetis AG Successfully Increases Series A Financing Round to EUR 24.5 Million
CD-Venture joins strong syndicate of existing VC investors.
Wednesday, May 18, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!